sarepta therapeutics fda - Search News

Order byBest matchMost fresh

News

Sarepta Will Resume Gene Therapy Shipments

· 3h · on MSN

Sarepta will resume gene therapy shipments after FDA review of recent patient death

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy.

Continue reading

FDA permits use of Sarepta Therapeutics’ Duchenne therapy in younger patients after short-lived halt

· 6h · on MSN

FDA Says Sarepta Can Resume Gene Therapy in Some Patients

Investing.com Australia8h

Sarepta Therapeutics gets FDA green light to resume Elevidys for DMD

Elevidys is an adeno-associated virus vector-based gene therapy that uses Sarepta’s AAVrh74 Platform Technology to treat DMD, ...

Fierce Pharma13h

FDA launches probe into new Elevidys death as Sarepta, Roche stress gene therapy not at fault

In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...

16h

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys

FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy ...

15hon MSN

Sarepta Stock Rises Despite Downgrade and FDA Probe. The Crisis Explained.

Sarepta shares gained even though the U.S. Food and Drug Administration said late Friday that it was probing the death of an ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results